A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.
Yannan FanMaria ArechederraSylvie RichelmeFabrice DaianChiara NovelloJulien CalderaroLuca Di TommasoGuillaume MorcretteSandra RebouissouMatteo DonadonEmanuela MorenghiJessica Zucman-RossiMassimo RoncalliRosanna DonoFlavio MainaPublished in: Hepatology (Baltimore, Md.) (2017)
Our genetic studies highlight the heightened vulnerability of liver cells to subtle changes in nononcogenic RTK levels, allowing them to acquire a molecular profile that facilitates the full tumorigenic program; furthermore, our outcomes uncover new synthetic lethal interactions as potential therapies for a cluster of HCC patients. (Hepatology 2017;66:1644-1661).
Keyphrases
- end stage renal disease
- ejection fraction
- induced apoptosis
- chronic kidney disease
- peritoneal dialysis
- climate change
- papillary thyroid
- emergency department
- type diabetes
- high throughput
- quality improvement
- genome wide
- cell cycle arrest
- risk assessment
- dna methylation
- adipose tissue
- cell proliferation
- gene expression
- copy number
- pi k akt
- childhood cancer
- endoplasmic reticulum stress
- single molecule
- glycemic control
- weight loss
- binding protein
- lymph node metastasis